{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:18:38Z","timestamp":1770221918059,"version":"3.49.0"},"reference-count":22,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,4,13]]},"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>For most gout patients, excruciatingly painful gout attacks are the major clinical burden of the disease. The goal of this study was to assess the association of frequent gout flares with healthcare burden, and to quantify how much lower gout-related costs and resource use are for those with infrequent flares compared to frequent gout flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Administrative claims data from a large US health plan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged 18\u2005years or above, and with evidence of gout based on medical and pharmacy claims between January 2009 and April 2012 were eligible for inclusion. Patient characteristics were assessed during a 12-month baseline period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Frequency of gout flares, healthcare costs and resource utilisation were assessed in the 12\u2005months following the first qualifying gout claim. Generalised linear models were employed to assess the impact of flare frequency on cost outcomes after adjusting for covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>102\u2005703 patients with gout met study inclusion criteria; 89\u2005201 had 0\u20131 gout flares, 9714 had 2 flares, and 3788 had 3+ flares. Average counts of gout-related inpatient stays, emergency room visits and ambulatory visits were higher among patients with 2 or 3+ flares, compared to those with 0\u20131 flares (all p&lt;0.001). Adjusted annual gout-related costs were $1804, $3014 and $4363 in those with 0\u20131, 2 and 3+ gout flares, respectively (p&lt;0.001 comparing 0\u20131 flares to 2 or 3+ flares).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gout-related costs and resource use were lower for those with infrequent flares, suggesting significant cost benefit to a gout management plan that has a goal of reducing flare frequency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-007214","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T21:26:00Z","timestamp":1435181160000},"page":"e007214","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis"],"prefix":"10.1136","volume":"5","author":[{"given":"Robert","family":"Jackson","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K","family":"Buysman","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Altan","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Korrer","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyon","family":"Choi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"2025121511053295000_5.6.e007214.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"issue":"(15 Suppl)","key":"2025121511053295000_5.6.e007214.2","first-page":"S459","article-title":"Clinical, humanistic, and economic outcomes of gout","volume":"11","author":"Brixner","year":"2005","journal-title":"Am J Manag Care"},{"key":"2025121511053295000_5.6.e007214.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"2025121511053295000_5.6.e007214.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2025121511053295000_5.6.e007214.5","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181945d2c"},{"key":"2025121511053295000_5.6.e007214.6","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903017966"},{"key":"2025121511053295000_5.6.e007214.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","article-title":"A revised estimate of the burden of illness of gout","volume":"75","author":"Wertheimer","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"key":"2025121511053295000_5.6.e007214.8","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112606"},{"key":"2025121511053295000_5.6.e007214.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081604"},{"key":"2025121511053295000_5.6.e007214.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.020"},{"key":"2025121511053295000_5.6.e007214.11","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"2025121511053295000_5.6.e007214.12","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1364"},{"key":"2025121511053295000_5.6.e007214.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-12-200412210-00009"},{"key":"2025121511053295000_5.6.e007214.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq363"},{"key":"2025121511053295000_5.6.e007214.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"2025121511053295000_5.6.e007214.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(98)00025-3"},{"key":"2025121511053295000_5.6.e007214.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00086-8"},{"key":"2025121511053295000_5.6.e007214.18","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2012.0057"},{"key":"2025121511053295000_5.6.e007214.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes183"},{"key":"2025121511053295000_5.6.e007214.20","first-page":"382","article-title":"Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population","volume":"20","author":"Doshi","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"2025121511053295000_5.6.e007214.21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3111\/13696998.2014.925905","article-title":"Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis","volume":"17","author":"Bron","year":"2014","journal-title":"J Med Econ"},{"key":"2025121511053295000_5.6.e007214.22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312474087"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-007214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:05:39Z","timestamp":1765825539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-007214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,24]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1136\/bmjopen-2014-007214"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-007214","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}